Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer (COMPASSION-13): a phase 2 study.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Cadonilimab combined with standard therapy was acceptable, with encouraging antitumor activity in patients with R/M CC.

Keyphrases